Private Equity
Adapsyn Bioscience Inc, a Hamilton, Ontario biotechnology company focused on natural-product drug candidates, has wrapped up an undisclosed round of financing. The deal was co-funded by Pfizer R&D Innovate, an affiliate of U.S. pharmaceutical giant Pfizer Inc and Genesys Capital, a Canadian life sciences venture capital firm. Genesys Managing Director Kelly Holman currently sits on the board. Adapsyn also announced it is partnering with Pfizer to identify and test undiscovered natural products, or organic biomolecules produced by nature, from Pfizer’s microbial strains. Adapsyn was founded in 2016 by CSO Nathan Magarvey.
3 min read · 11 January 2018
Braeburn Pharmaceuticals, which provides treatment solutions for opioid addiction, has secured $110 million in financing. Wellington Capital Management led the round with participation from other investors that included Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management, Rock Springs Capital and Apple Tree Partners.
1 min read · 11 January 2018
New York-based Pager, a mobile-first patient engagement and care navigation platform for large health plans and health systems, has raised an undisclosed amount of funding. Horizon Healthcare Services led the round with participation from other investors that included Lux Capital, Goodwater Capital, New Enterprise Associates and Vero Norte.
1 min read · 11 January 2018
2 min read · 10 January 2018
3 min read · 10 January 2018
1 min read · 10 January 2018
Palo Alto, California-based Sync-Think Inc, a developer of eye-tracking technology products, has secured $3.5 million in funding. Quadrant Management Inc led the round.
3 min read · 10 January 2018
2 min read · 10 January 2018
Renault-Nissan-Mitsubishi said it established Alliance Ventures, a corporate venture fund with the potential to invest up to $1 billion over five years.
1 min read · 09 January 2018
Canadian venture capital firm Pangaea Ventures has started tracking and reporting on the impact of its portfolio of advanced-materials companies. The firm is measuring impact across four categories: carbon dixoide reduction, fresh water produced or saved, food production increased, and lives impacted. It will produce an estimated cumulative impact of the portfolio by the end of 2025. General Partner Chris Erickson, who founded Pangaea in 2000, said tracking and reporting on the sustainability and social impact of the firm's portfolio is "the next logical step to maintain a leadership position.”
2 min read · 09 January 2018
